Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A quality of life questionnaire for patients with scapula alata (SA-Q): development and validation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Responsiveness of clinical tests for people with neck pain

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cementless metaphyseal sleeves without stem in revision total knee arthroplasty

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage explants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Shu Sun
  • Anne-Christine Bay-Jensen
  • Morten A Karsdal
  • Anne Sofie Siebuhr
  • Qinlong Zheng
  • Walter P Maksymowych
  • Thorbjørn G Christiansen
  • Kim Henriksen
Vis graf over relationer

BACKGROUND: Matrix metalloproteinase-3 (MMP-3) plays an important role in the pathology of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Measurement of active MMP-3 in clinical samples could provide information about progression of rheumatoid diseases, and potentially response to treatment. Hence, we aimed to develop a sensitive assay specifically measuring the active form of MMP-3 (act-MMP-3) both in ex vivo models and in human sera.

METHODS: A monoclonal antibody against the first 6 amino acids of act-MMP-3 was developed, and the specificity was carefully tested by comparing total and active MMP-3. A technically robust act-MMP-3 ELISA was produced. For biological validation, human synovial membrane and human cartilage explant (HEX) culture models were measured and compared by ELISA and immunoblots. For clinical relevance, the serum levels of act-MMP-3 in AS and RA patients before and after anti-TNF-α treatment were evaluated.

RESULTS: A highly specific and technically robust ELISA detecting act-MMP-3 in serum was developed. The lower limit of detection was 33.7 pg/mL. The dilution and spiking recovery of human serum was within 100 ± 20%. The average intra- and inter-assay variations were 3.1% and 13.5% respectively.High levels of act-MMP-3 expression were observed in human synovial membrane culture and oncostatin M and TNF-α stimulated human cartilage. In a cross-sectional study of both AS and RA patients, serum act-MMP-3 level was correlated with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). In addition, in patients receiving anti-TNF-α treatment, the serum level of act-MMP-3 was significantly reduced compared to baseline level reflecting the anti-inflammatory effects of the treatment.

CONCLUSION: We have successfully developed an assay measuring act-MMP-3 in human serum showing correlation to inflammatory markers. Further studies are required to clarify, whether act-MMP-3 can serve as a predictive marker for outcome in chronic rheumatoid disorders.

OriginalsprogEngelsk
TidsskriftB M C Musculoskeletal Disorders
Vol/bind15
Sider (fra-til)93
ISSN1471-2474
DOI
StatusUdgivet - 2014

ID: 45107842